Shionogi & Co., Ltd. acquires Viiv Healthcare

Shionogi has agreed to acquire Pfizer’s 11.7% stake in ViiV Healthcare for $2.1 billion, a move that leaves ViiV's shareholder structure streamlined with only Shionogi and GSK holding shares. This acquisition underscores Shionogi’s intensified commitment to the HIV treatment market, raising its stake in the specialist firm to 21.7%, while GSK remains the majority shareholder with 78.3%.

The financial terms delineate a transaction amounting to $2.125 billion payable by Shionogi and $1.875 billion to be received by Pfizer. Additionally, GSK is slated to receive a special dividend of $250 million. This arrangement alters the composition of ViiV's ownership, which was initially formed in 2009 as a joint initiative by Pfizer and GSK to focus on innovations in HIV treatment and prevention. The transaction is expected to close in the first quarter of 2026, contingent upon necessary regulatory approvals.

For Shionogi, the acquisition consolidates its influence in ViiV Healthcare and emphasizes its strategic focus on HIV-related research and development. The collaboration between Shionogi and GSK seeks to further ViiV’s efforts in advancing a pipeline of long-acting injectable treatments for HIV. Shionogi’s long-standing commitment to addressing major infectious diseases is epitomized by their role in developing key therapeutic technologies such as integrase inhibitors.

With Pfizer's exit from ViiV, the market for HIV therapeutics remains competitive but less fragmented, allowing GSK and Shionogi to potentially streamline operations and focus more tightly on product development. This transaction also enables GSK to terminate its financial obligation related to Pfizer’s put option liability, impacting the company's earnings and allowing alignment of financial metrics.

The anticipated conclusion of the acquisition transaction in 2026 hinges on acquiring all pertinent regulatory permissions. Once finalized, Shionogi and GSK are poised to guide ViiV’s future trajectory with a sharpened focus on its research agenda, further consolidating their partnership established over the past decade.